BioCentury
ARTICLE | Clinical News

CARsgen solid tumor CAR T leads to complete response

September 14, 2018 3:19 PM UTC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The product comprises autologous CAR T cells targeting claudin 18 (CLDN18) splice variant 2.

The company said eight of 12 patients in the trial experienced tumor regression of varying degrees, with five of six patients who received an "optimized" dose of CAR-CLD18 T cells achieving the objective responses. The therapy was well tolerated. Changhai Hospital is sponsoring the open-label, Chinese trial in collaboration with CARsgen...